Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2008-5-23
pubmed:abstractText
Evidences suggest that lipopolysaccharide (LPS) participates in the inflammatory response in the cardiovascular system; however, it is unknown if LPS is sufficient to cause the cardiac hypertrophy. In the present study, we treated H9c2 myocardiac cells with LPS to explore whether LPS causes cardiac hypertrophy, and to identify the precise molecular and cellular mechanisms behind hypertrophic responses. Here we show that LPS challenge induces pathological hypertrophic responses such as the increase in cell size, the reorganization of actin filaments, and the upregulation of hypertrophy markers including atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in H9c2 cells. LPS treatment significantly promotes the activation of GATA-4 and the nuclear translocation of NFAT-3, which act as transcription factors mediating the development of cardiac hypertrophy. After administration of inhibitors including U0126 (ERK1/2 inhibitor), SB203580 (p38 MAPK inhibitor), SP600125 (JNK1/2 inhibitor), CsA (calcineurin inhibitor), FK506 (calcineurin inhibitor), and QNZ (NFkappaB inhibitor), LPS-induced hypertrophic characteristic features, such as increases in cell size, actin fibers, and levels of ANP and BNP, and the nuclear localization of NFAT-3 are markedly inhibited only by calcineurin inhibitors, CsA and FK506. Collectively, these results suggest that LPS leads to myocardiac hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 cells. Our findings further provide a link between the LPS-induced inflammatory response and the calcineurin/NFAT-3 signaling pathway that mediates the development of cardiac hypertrophy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0300-8177
pubmed:author
pubmed:issnType
Print
pubmed:volume
313
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
167-78
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:18398669-Actins, pubmed-meshheading:18398669-Animals, pubmed-meshheading:18398669-Atrial Natriuretic Factor, pubmed-meshheading:18398669-Biological Markers, pubmed-meshheading:18398669-Calcineurin, pubmed-meshheading:18398669-Cell Nucleus, pubmed-meshheading:18398669-Cell Size, pubmed-meshheading:18398669-Fluorescent Antibody Technique, pubmed-meshheading:18398669-GATA4 Transcription Factor, pubmed-meshheading:18398669-Gene Expression Regulation, pubmed-meshheading:18398669-Hypertrophy, pubmed-meshheading:18398669-Lipopolysaccharides, pubmed-meshheading:18398669-Models, Biological, pubmed-meshheading:18398669-Myocytes, Cardiac, pubmed-meshheading:18398669-NFATC Transcription Factors, pubmed-meshheading:18398669-Natriuretic Peptide, Brain, pubmed-meshheading:18398669-Rats, pubmed-meshheading:18398669-Signal Transduction, pubmed-meshheading:18398669-Up-Regulation
pubmed:year
2008
pubmed:articleTitle
Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 myocardiac cells.
pubmed:affiliation
Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan.
pubmed:publicationType
Journal Article